Genmab — December 2023
-
"Key pharmaceuticals like Darzalex, Carvykti, and Stelara are pivotal revenue drivers, illustrating J&J's steadfast commitment to developing and delivering life-altering treatments. These flagship drugs continue to showcase robust market demand, underpinning the company's revenue expectations"
. -
On the linvoseltamab data earlier by lahn ; all patients treated with 200 mg experienced an adverse event (AE), including 85% who experienced Grade ≥3 adverse events (AE). / Deaths due to treatment-emergent AEs on-treatment or within 30 days post last dose occurred in 14 patients (12%) https://investor.regeneron.com/news-releases/news-release-details/updated-linvoseltamab-pivotal-data-demonstrated-strong-rates-and
-
In the corresponding ph 1-2 study of teclistamab responserates were slightly lover. AEs about the same. https://www.nejm.org/doi/full/10.1056/NEJMoa2203478
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind